SCHERING OTC MUSCLE RELAXANT LEGATRIN INTRODUCTION PLANNED FOR 1985
SCHERING OTC MUSCLE RELAXANT LEGATRIN INTRODUCTION PLANNED FOR 1985, Schering Exec VP Richard Kogan told health care analysts in New York June 20. "This year, we are introducing five new foot products that will take advantage of the new trend toward better footcare, and we are also coming out with an OTC muscle relaxant, Legatrin, that is aimed at the millions of adult Americans who suffer the pain of leg cramps at night," Kogan commented. Also in the OTC area, Kogan reported that Schering is to launch additional new products over "the next several months, one of which includes what might be a major new product in the diet and weight maintenance category." The product, FiberTrim, consisting of fiber from grain and citrus, has been marketed in select areas since mid-March. It is sold in 100 and 250 tab bottles. In an effort to strengthen its OTC marketing, Schering is combining its promotion to health-care professions with consumer advertising, Kogan said. For example, he noted that two months ago the company started a national radio campaign for Tinactin, and ads are planned for magazines such as Newsweek and Sports Illustrated. "We're also working hard to use our well-known brand names as launching platforms for new products," Kogan said. Noting that Correctol was one of Schering's most successful brands in 1984 with U.S. sales of $31 mil., a 10% share of the laxative market, Kogan said Schering will soon introduce "Correctol bulk laxative with an allnatural fruit fiber base to compete with Metamucil."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth